Minerva Neurosciences, Inc. (4MNA.F)
Frankfurt · EUR · Healthcare · Biotechnology
€1.94 (+1.30%) as of
Key statistics
- Market cap
- 92.77M
- EPS (TTM)
- -29.2000
- Dividend yield
- 0.00%
- 52-week range
- 1.8650 – 6.8000
- Beta
- -0.12
- Profit margin
- 0.00%
- Volume
- 12.00
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Burlington, MA, United States
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.